Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.61 |
| ▸ | MMP2 | P08253 | 2/20 | 0.58 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.58 |
| ▸ | MMP13 | P45452 | 1/20 | 0.58 |
| ▸ | MMP14 | P50281 | 1/20 | 0.58 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.58 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5945539 | 1.00 | SPPL2A (0.61) | SPPL2AMMP2ADAMTS4MMP13MMP14 | |
| SCHEMBL1058892 | 0.95 | SPPL2A (0.67) | SPPL2AMMP2ADAMTS4MMP13MMP14 | |
| SCHEMBL1058690 | 0.93 | SPPL2A (0.69) | SPPL2A | |
| SCHEMBL14602719 | 0.93 | SPPL2A (0.69) | SPPL2A | |
| SCHEMBL7905239 | 0.93 | SPPL2A (0.69) | SPPL2A | |
| SCHEMBL15355882 | 0.90 | SPPL2A (0.61) | SPPL2A | |
| SCHEMBL7419618 | 0.87 | SPPL2A (0.67) | SPPL2AMMP2ADAMTS4MMP13MMP14 | |
| SCHEMBL28738327 | 0.87 | SPPL2A (0.60) | SPPL2AKEAP1 | |
| SCHEMBL28628358 | 0.87 | SPPL2A (0.60) | SPPL2AKEAP1 | |
| SCHEMBL28628356 | 0.87 | SPPL2A (0.60) | SPPL2AKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130172295-A1 | PROCESS FOR PREPARATION OF HIV PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-8431745-B2 | Process for preparation of HIV protease inhibitors | GILEAD SCIENCES, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120258935-A1 | PROCESS FOR PREPARATION OF HIV PROTEASE INHBITORS | GILEAD SCIENCES, INC. (US) | 2012-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172295-A1 | PROCESS FOR PREPARATION OF HIV PROTEASE INHIBITORS | PRSS1, PREP, SERPINB1 | SPPL2A 1280/4885MMP2 199/4885ADAMTS4 233/4885 |
| US-20120258935-A1 | PROCESS FOR PREPARATION OF HIV PROTEASE INHBITORS | PREP, FURIN, PRSS1 | SPPL2A 1299/4885MMP2 114/4885ADAMTS4 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.